The Vitafoods Asia 2026 preview places Cerenity™ among offers targeting mobility, strength and vitality. The product combines three proprietary probiotic strains and is directed particularly towards ageing or sedentary populations.

The signal is the commercial maturation of the gut–muscle axis. The microbiome is being connected with physical performance and healthy ageing, creating potential product architectures with protein, creatine, fibre and other nutritional support.

Cerenity is not an absolute debut: company materials presented it earlier. Lallemand reports an RCT in 64 older adults using 6 billion CFU plus 900 mg inulin, but until the full paper is available, effect magnitude, analysis and replicability cannot be independently assessed.

Why it matters

For ingredient suppliers and brands, the signal opens formulation and differentiation space beyond traditional digestive-health positioning.

Evidence limit

A commercial signal, not a new peer-reviewed result. The company cites a 64-person study with inulin, but the full manuscript remains unpublished and does not isolate the blend alone.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · NutraIngredients ↗